These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410 [TBL] [Abstract][Full Text] [Related]
10. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia. Sun WT; Xiang W; Ng BL; Asari K; Bunte RM; Casey PJ; Wang M; Chuah C Exp Hematol; 2016 Mar; 44(3):189-93.e2. PubMed ID: 26706195 [TBL] [Abstract][Full Text] [Related]
13. Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells. Tsubaki M; Takeda T; Kino T; Sakai K; Itoh T; Imano M; Nakayama T; Nishio K; Satou T; Nishida S Oncotarget; 2017 Jun; 8(24):38717-38730. PubMed ID: 28418880 [TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1. Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934 [TBL] [Abstract][Full Text] [Related]
15. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function. Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074 [TBL] [Abstract][Full Text] [Related]
16. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells. Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755 [TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model. Carter BZ; Mak PY; Mu H; Wang X; Tao W; Mak DH; Dettman EJ; Cardone M; Zernovak O; Seki T; Andreeff M Haematologica; 2020 May; 105(5):1274-1284. PubMed ID: 31371419 [TBL] [Abstract][Full Text] [Related]
18. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Scherr M; Chaturvedi A; Battmer K; Dallmann I; Schultheis B; Ganser A; Eder M Blood; 2006 Apr; 107(8):3279-87. PubMed ID: 16278304 [TBL] [Abstract][Full Text] [Related]
19. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Scopim-Ribeiro R; Machado-Neto JA; Eide CA; Coelho-Silva JL; Fenerich BA; Fernandes JC; Scheucher PS; Savage Stevens SL; de Melo Campos P; Olalla Saad ST; de Carvalho Palma L; de Figueiredo-Pontes LL; Simões BP; Rego EM; Tognon CE; Druker BJ; Traina F Invest New Drugs; 2021 Jun; 39(3):736-746. PubMed ID: 33403501 [TBL] [Abstract][Full Text] [Related]
20. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach. Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]